Showing results (51-60 of 80) with videos related to
Sort By:
Pageof 8
Cancer Immunology Research|December 20, 2019
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell ResponsesSamantha K Greaney, Alain P Algazi, Katy K Tsai, et al.Journal for Immunotherapy of Cancer|May 24, 2019
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance studyDouglas B Johnson, Ali Manouchehri, Alexandra M Haugh, et al.Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivoChristian Posch, Homayoun Moslehi, Luzviminda Feeney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignanciesJade Homsi, George R Simon, Chris R Garrett, et al.Journal of the American Academy of Dermatology|October 6, 2018
The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control studyKara E Walton, Erin M Garfield, Bin Zhang, et al.Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.Molecular Cancer Research : MCR|March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor ImmunityMia Han, Bianca Nguyen, Jack Y Lee, et al.Annals of Surgical Oncology|June 4, 2020
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced MelanomaLauren S Levine, Kelly M Mahuron, Katy K Tsai, et al.JCI Insight|July 21, 2017
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapyKimberly Loo, Katy K Tsai, Kelly Mahuron, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.Pageof 8